Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (1,544)	$ (2,455)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sales of in process research and development	(445)	(144)
Stock-based compensation expense	71	397
Changes in operating assets and liabilities:
Prepaid expenses and other assets	149	2,192
Accounts payable, accrued expenses and other	27	(208)
Net cash used in operating activities	(1,742)	(218)
Cash flows from investing activities
Proceeds from sale of in-process research and development assets	445	144
Net cash provided by investing activities	445	144
Cash flows from financing activities
Proceeds from exercise of options	6,533	239
Net cash provided by (used in) financing activities	6,533	239
Net increase (decrease) in cash and cash equivalents	5,236	165
Cash and cash equivalents, beginning of period	14,203	14,038
Cash and cash equivalents, end of period	$ 19,439	$ 14,203